Form 4: Revolution Medicines Executive Sells Shares
Insider Transaction (Form 4)
Stephen Michael Kelsey, See Remarks of Revolution Medicines, Inc., sold 92,531 shares of common stock on September 11, 2026.
Summary
- Option exercise/conversion: acquired 52,500 Common Stock at $42.45 ($2,228,625) on September 11, 2026; holds 344,376 after (Direct).
- Option exercise/conversion: acquired 40,031 Common Stock at $40.74 ($1,630,863) on September 11, 2026; holds 384,407 after (Direct).
- Open-market sale: disposed of 800 Common Stock at $198.55 ($158,840) on September 11, 2026; holds 383,607 after (Direct).
- Open-market sale: disposed of 11,833 Common Stock at $200.11 ($2,367,955) on September 11, 2026; holds 371,774 after (Direct).
- Open-market sale: disposed of 13,368 Common Stock at $200.78 ($2,683,986) on September 11, 2026; holds 358,406 after (Direct).
- Open-market sale: disposed of 21,447 Common Stock at $201.75 ($4,326,947) on September 11, 2026; holds 336,959 after (Direct).
- Open-market sale: disposed of 18,869 Common Stock at $203.06 ($3,831,550) on September 11, 2026; holds 318,090 after (Direct).
- Open-market sale: disposed of 17,949 Common Stock at $203.87 ($3,659,309) on September 11, 2026; holds 300,141 after (Direct).
- Open-market sale: disposed of 4,995 Common Stock at $204.84 ($1,023,189) on September 11, 2026; holds 295,146 after (Direct).
- Open-market sale: disposed of 3,270 Common Stock at $205.81 ($672,991) on September 11, 2026; holds 291,876 after (Direct).
- Option exercise/conversion: disposed of 52,500 Stock Option (Right to Buy) at $42.45 ($2,228,625) on September 11, 2026 (Direct).
- Option exercise/conversion: disposed of 40,031 Stock Option (Right to Buy) at $40.74 ($1,630,863) on September 11, 2026; holds 88,069 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $18,724,767 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Stephen Michael Kelsey — Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Option exercise/conversion | Common Stock | 52,500 | $42 | $2.2M | 344,376 |
| 2026-09-11 | Option exercise/conversion | Common Stock | 40,031 | $41 | $1.6M | 384,407 |
| 2026-09-11 | Open-market sale | Common Stock | 800 | $199 | $158.8K | 383,607 |
| 2026-09-11 | Open-market sale | Common Stock | 11,833 | $200 | $2.4M | 371,774 |
| 2026-09-11 | Open-market sale | Common Stock | 13,368 | $201 | $2.7M | 358,406 |
| 2026-09-11 | Open-market sale | Common Stock | 21,447 | $202 | $4.3M | 336,959 |
| 2026-09-11 | Open-market sale | Common Stock | 18,869 | $203 | $3.8M | 318,090 |
| 2026-09-11 | Open-market sale | Common Stock | 17,949 | $204 | $3.7M | 300,141 |
| 2026-09-11 | Open-market sale | Common Stock | 4,995 | $205 | $1.0M | 295,146 |
| 2026-09-11 | Open-market sale | Common Stock | 3,270 | $206 | $673.0K | 291,876 |
| 2026-09-11 | Option exercise/conversion | Stock Option (Right to Buy) | 52,500 | $42 | $2.2M | 0 |
| 2026-09-11 | Option exercise/conversion | Stock Option (Right to Buy) | 40,031 | $41 | $1.6M | 88,069 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Option exercise/conversion (52,500 shares) |
| 2026-09-11 | Option exercise/conversion (40,031 shares) |
| 2026-09-11 | Open-market sale (800 shares) |
| 2026-09-11 | Open-market sale (11,833 shares) |
| 2026-09-11 | Open-market sale (13,368 shares) |
| 2026-09-11 | Open-market sale (21,447 shares) |
| 2026-09-11 | Open-market sale (18,869 shares) |
| 2026-09-11 | Open-market sale (17,949 shares) |
| 2026-09-11 | Open-market sale (4,995 shares) |
| 2026-09-11 | Open-market sale (3,270 shares) |
| 2026-09-11 | Option exercise/conversion (52,500 shares) |
| 2026-09-11 | Option exercise/conversion (40,031 shares) |
Keywords
insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Stephen Michael Kelsey
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.